WHO documents

WHO preferred product characteristics: endectocide for malaria transmission control (here)

This document defines the key questions that an endectocide (using ivermectin as a prototype) research agenda should address to generate the appropriate evidence required to define a WHO policy position on the role of an endectocide in the reduction of malaria transmission.

Publication date: 2017

Malaria Policy Advisory Committee meeting report (September 2016) (here)

On 14–16 September 2016, the WHO Malaria Policy Advisory Committee (MPAC) convened to review updates and progress, and provide guidance with respect to specific thematic areas of work carried out by the Global Malaria Programme.

The meeting focused on: (1) an update on the RTS,S vaccine pilot implementation programme; (2) an update on the malaria elimination in the Greater Mekong subregion; (3) a review of Malaria elimination: an operational manual; (4) the results from a multi-country evaluation of the impact of insecticide resistance on malaria vector control; (5) an update on the Strategic Advisory Group on malaria eradication; (6) an update on the development of guidelines for malaria vector control; (7) the development of the Global Vector Control Response; (8) a proposed evidence review group to consider the cardiotoxicity of antimalarial medicines; (9) a report on the WHO technical consultation on detection and surveillance of HRP2/HRP3 deletions; (10) recommendations for the surveillance, monitoring and evaluation taskforce; (11) a proposed evidence review group to review Plasmodium knowlesi; (12) the proposed target product profile for ivermectin; and (13) proposed plans for the World Malaria Report.

Publication date: 2016

MPAC meeting, 14-16 September 2016. Session 9: Update on a proposed Ivermectin target product profile

Backgound (here)

Presentation (here)

Malaria Journal Collection: Ivermectin to reduce malaria transmission

Hundreds of millions of people have received ivermectin every year in campaigns against onchocerciasis and lymphatic filariasis with excellent safety profile. It is also an endectocide, a drug capable of killing mosquitoes feeding on treated subjects.

In the face of the challenges posed by insecticide resistance and residual transmission, mass drug administration of endectocides holds potential as a complementary strategy for malaria elimination.

Mounting evidence suggests that mass-treatment of humans (or their livestock) with ivermectin can reduce vector survival and help reduce malaria transmission. There are however numerous knowledge gaps regarding the appropriate dosing, trial design and regulatory pathway for such a novel approach.

This ‘Ivermectin to reduce malaria transmission’ thematic series in the Malaria Journal aims at providing a comprehensive assessment and factors to consider in adapting this tool for a potential new indication.

Check the series of articles and commentaries here.

– Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety (here)

– Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway (here)

– Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways (here)


 Academic publications

– Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya (here)

– Studies assessing the effect of ivermectin on the survival of Anopheles mosquitoes (here)

– Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus (here)

– Treatment of livestock with systemic insecticides for control of Anopheles arabiensis in western Kenya (here)

– Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals (here)

– Administration of ivermectin to peridomestic cattle: a promising approach to target the residual transmission of human malaria (here)

– Effect of ivermectin on the larvae of Anopheles gambiae and Culex quinquefasciatus (here)

– Filling gaps on ivermectin knowledge: effects on the survival and reproduction of Anopheles aquasalis, a Latin American malaria vector (here)

– Incidental mosquitocidal effect of an ivermectin mass drug administration on Anopheles farauti conducted for scabies control in the Solomon Islands (here)

– Ivermectin-treated cattle reduces blood digestion, egg production and survival of a free-living population of Anopheles arabiensis under semi-field condition in south-eastern Tanzania (here)

– Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles (here)

– Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae (here)

– Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments (here)

– Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae (here)

– What does not kill it makes it weaker: effects of sub-lethal concentrations of ivermectin on the locomotor activity of Anopheles aquasalis (here)

– Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors (here)

– Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector Anopheles darlingi (here)

– Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control (here)

– Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages (here)

– Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination (here)

– The repurposing of ivermectin for malaria: a prospective pharmacokinetics-based virtual clinical trials assessment of dosing regimen options (here)

– Differential susceptibilities of Anopheles albimanus and Anopheles stephensi mosquitoes to ivermectin (here)

– Ivermectin: repurposing an old drug to complement malaria vector control (here)

– Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial (here)

Other relevant documents

Medicines for Malaria Venture: Target product profiles & target candidate profiles (here)